Key result
High-throughput screening identifies 52 small molecules that protect myoblasts from DUX4-induced toxicity.
Why the study?
DUX4 protein expression causes toxicity in FSHD, and identifying inhibitors of DUX4-induced toxicity is critical for therapeutic development.
Population
C2C12 myoblasts overexpressing DUX4, 3T3 fibroblasts, and human cells
Comparison
44,000 small, drug-like molecules screened for inhibition of DUX4-induced toxicity
Design
High-throughput screening with secondary validation assays
Authors
Loading...
May guide FSHD drug discovery targeting oxidative stress; leaves open in vivo efficacy and clinical translation.
High-throughput screening identified small molecules that inhibit DUX4-induced toxicity, suggesting that enhancing the oxidative stress response pathway may be a therapeutic strategy for Facioscapulohumeral muscular dystrophy.
Bosnakovski et al. (2014) studied Facioscapulohumeral muscular dystrophy (FSHD). Small molecule inhibitors vs. Vehicle/Control was evaluated on Cell viability (protection from DUX4-induced toxicity). High-throughput screening of 44,000 small molecules identified 52 compounds that protect myoblasts from DUX4-induced toxicity, with 60% also protecting against oxidative stress.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: